Partnered Research and Development

• AstraZeneca Collaboration
• ASLAN Pharmaceuticals
• Genentech Collaboration
• Celgene Collaboration
• InterMune Collaboration
• Amgen Collaboration
• Novartis Collaboration

Our significant and / or recent collaborators under our partnered programs include:

• Amgen - We entered into a worldwide strategic collaboration with Amgen in December 2009 to develop and commercialize our glucokinase activator, AMG 151, which is currently in Phase 2 development for Type 2 diabetes, and to discover potential back-up compounds for AMG 151.
• ASLAN Pharmaceuticals - We entered into a collaboration and license agreement with ASLAN Pharmaceuticals in July 2011 to develop Array’s HER2 / EGFR inhibitor, ARRY-543, or ASLAN001, which is currently in a Phase 2 clinical trial in patients with gastric cancer.
• AstraZeneca - In December 2003, we entered into a collaboration and license agreement with AstraZeneca under which AstraZeneca received a license to three of our MEK inhibitors for cancer, including selumetinib, which is currently in multiple Phase 2 clinical trials.
• Celgene - We entered into a worldwide strategic collaboration agreement with Celgene in September 2007 focused on the discovery, development and commercialization of novel therapeutics in cancer and inflammation.
• Genentech - We entered into a worldwide strategic collaboration agreement with Genentech in January 2003, which was expanded in 2005, 2008, and 2009, and is focused on the discovery, development and commercialization of novel therapeutics. The most advanced drug is GDC-0068, an AKT inhibitor for cancer, which is currently in a Phase 2 trial.
• In August 2011, we entered into an oncology partnership with Genentech for the development of each company’s small molecule Checkpoint kinase 1 (Chk-1) program. The programs include Genentech’s compound GDC-0425 (RG7602) and Array’s compound, GDC-0575, both of which are in Phase 1 clinical trials in patients with cancer.
• Novartis - We entered into a worldwide strategic collaboration with Novartis in April 2010 to develop and commercialize our MEK inhibitor, MEK162, and other MEK inhibitors identified in the agreement. MEK162 is currently in numerous Phase 1b and Phase 2 clinical trials in patients with cancer.
• InterMune (program acquired by Roche) - We entered into a collaboration with InterMune in 2002, which resulted in the joint discovery of danoprevir, a novel small molecule inhibitor of the Hepatitis C Virus NS3/4A protease. Roche Holding AG acquired danoprevir from InterMune in 2010. Danoprevir is currently in Phase 2b clinical trials.

We have received a total of $577.9 million in research funding and in up-front and milestone payments from our collaboration partners from inception through June 30, 2012, including $174 million in initial payments from our strategic collaborations with Amgen, Genentech and Novartis we entered into over the past 32 months. These three collaborations entitle Array to receive up to over $2.2 billion in additional potential milestone payments if all clinical and commercialization milestones under the agreements are achieved, double digit royalties and/or commercial co-detailing rights. With our other existing partnered programs, Array is entitled to receive a total of over $3.6 billion in additional potential milestone payments if we or our collaborators achieve the drug discovery, development and commercialization objectives detailed in those agreements. We also have the potential to earn royalties on any resulting product sales or share in the proceeds from development or commercialization arrangements resulting from 11 drug research and development programs.

If you are interested in learning more about our proprietary pipeline or collaborating with Array, please contact our Business Development group:

Phone: 303.381.6611
E-mail: bd@arraybiopharma.com

New Collaboration Business Development
Contact: Conrad Hummel, Ph.D
Phone: 303.381.6645
E-mail: chummel@arraybiopharma.com